Novel drying method for advanced materials

Acapsil是一种ce认证的新型先进生物材料，已被证明在伤口护理中有效果。在英国，每年有220万例伤口需要治疗，这给国民保健服务系统带来了53亿英镑的直接费用。对于急性和慢性伤口和溃疡的住院患者，Acapsil可使伤口愈合加速60%，并将住院天数减少31%。据估计，Acapsil可将伤口护理费用降低25-30%。Acapsil在全球所有主要市场都获得了专利。Acapsil的性能在很大程度上取决于制造过程，目前该过程中的一个步骤正在阻止大规模生产。为了解决这个问题，已经进行了大量的研究，并找到了一种解决方案，这种解决方案已经在一个小型试点模型中进行了测试和证明。这个项目的目的是建立一个全尺寸的原型模型，以达到最终的设计，可以形成Acapsil生产线的基础。没有这一点，就不可能生产出满足医疗需要的Acapsil。这将意味着失去帮助创伤患者的机会，以及失去对英国重要的出口和就业机会。

Acapsil is a CE-marked novel first-in-class advanced biomaterial, which has demonstrated effects in wound care. Annually in the UK, 2.2 mill wounds require treatment causing direct costs to the NHS of £5.3 bn. Acapsil accelerates wound healing by 60% and reduces bed-days by 31% for hospital in-patients with acute and chronic wounds and ulcers. Estimates indicate that Acapsil can reduce the costs of wound care by 25-30%. Acapsil is patented in all major markets world-wide. The properties of Acapsil are to a high degree determined by the manufacturing process and currently a single step in the process is preventing large-scale manufacturing. Considerable research has been dedicated to solving this problem and a solution has been found which has been tested and demonstrated to work in a small pilot model. The purpose of this project is to build a full-scale prototype model to reach a final design that can form the basis for a manufacturing line for Acapsil. Without this, it will not be possible to produce Acapsil to cover the medical need. This will mean lost opportunity to help patients with debilitating wounds and loss of important export and job opportunites to the UK.